Research - The recent decline in the price of Conatus Pharmaceuticals (CNAT) mirrors the pullback in small-cap stocks, though CNAT fell out of favor in-part due to the delay of … Continue Reading
PremiumResearch - Why we're booking gains on Keryx (KERX) and an options strategy for the Sept. 7 PDUFA decision on Zerenex.
Read nowResearch - Roche (RHHBY) is purchasing InterMune (ITMN) for $8.3B, or $74 per share in cash. Admittedly, this caught me off guard. The world’s leading provider of cancer care products is better known … Continue Reading
Read nowResearch - InterMune’s (ITMN) stock rose 14 percent last Wednesday, closing at a 14-year high of $52.06, on rumors that big pharma is lining up to bid for … Continue Reading
Read nowResearch - Success for Amicus Therapeutics (FOLD) in a study of migalastat meant +50% for PropThink subscribers who followed our trade recommendation.
Read nowResearch - Takeaways from OncoGeneX's (OGXI). Knowing this could make or save you some $$.
PremiumResearch - Amicus Therapeutics (FOLD), with a current market value of just $271 million, represents a high-risk, high reward play for investors willing to bet that the … Continue Reading
Premium
